All companies
Visit website
RETROPERC MEDICAL PRODUCTS, INC
OperatingRetroPerc Medical Products, Inc.
Healthcare · Technology · Founded 2024
Superior Nephrostomy creation
Post-money valuation ⓘ
$9.5M
As of Oct 2024 · from RetroPerc Medical Products, Inc Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$0
Across 1 round since 2024
Latest share price
$1.06
RetroPerc Medical Products, Inc Common Stock 1 offering price
Financials
FY2022–FY2023 · from SEC filings · hover any figure for its source$112K
−$29K
2022
$147K
−$29K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
Income statement
Revenue
$111,866
$146,893
Cost of goods sold
$13,764
$7,252
Gross margin
88%
95%
Net income
-$29,098
-$29,450
Taxes paid
$0
$0
Balance sheet
Cash
$1,059
$3,418
Accounts receivable
$13,120
$14,100
Total assets
$36,103
$89,614
Short-term debt
$9,774
$2,980
Long-term debt
$0
$0
Total liabilities
$9,774
$2,980
Other
Headcount
—
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$9.5M
post-money
RetroPerc Medical Products, Inc Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $1.2MInvestors 0Post-money $9.5M
Reg CF annual-report compliance
Not obligated
never closed a Reg CF raise
0 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0002038087Share price $1.06
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.